- Home
- OTLK vs LRFC Comparison
OTLK vs LRFC Comparison
Compare OTLK & LRFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- LRFC
- Stock Information
- Founded
- OTLK 2010
- LRFC 2013
- Country
- OTLK United States
- LRFC United States
- Employees
- OTLK N/A
- LRFC N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- LRFC Finance: Consumer Services
- Sector
- OTLK Health Care
- LRFC Finance
- Exchange
- OTLK Nasdaq
- LRFC Nasdaq
- Market Cap
- OTLK 48.3M
- LRFC 50.2M
- IPO Year
- OTLK 2016
- LRFC 2013
- Fundamental
- Price
- OTLK $1.57
- LRFC $18.86
- Analyst Decision
- OTLK Strong Buy
- LRFC
- Analyst Count
- OTLK 5
- LRFC 0
- Target Price
- OTLK $9.60
- LRFC N/A
- AVG Volume (30 Days)
- OTLK 796.7K
- LRFC 11.2K
- Earning Date
- OTLK 08-13-2025
- LRFC 08-07-2025
- Dividend Yield
- OTLK N/A
- LRFC 7.58%
- EPS Growth
- OTLK N/A
- LRFC N/A
- EPS
- OTLK 0.83
- LRFC N/A
- Revenue
- OTLK N/A
- LRFC $20,544,000.00
- Revenue This Year
- OTLK N/A
- LRFC N/A
- Revenue Next Year
- OTLK $379.84
- LRFC N/A
- P/E Ratio
- OTLK $1.91
- LRFC N/A
- Revenue Growth
- OTLK N/A
- LRFC 3.11
- 52 Week Low
- OTLK $0.87
- LRFC $16.57
- 52 Week High
- OTLK $9.25
- LRFC $26.00
- Technical
- Relative Strength Index (RSI)
- OTLK 40.37
- LRFC 56.05
- Support Level
- OTLK $1.65
- LRFC $18.53
- Resistance Level
- OTLK $2.04
- LRFC $19.00
- Average True Range (ATR)
- OTLK 0.12
- LRFC 0.39
- MACD
- OTLK -0.03
- LRFC 0.18
- Stochastic Oscillator
- OTLK 2.13
- LRFC 77.87
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About LRFC Logan Ridge Finance Corporation
Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.